The $3,000 mattress cover company that billionaires love wants to become a healthcare company
Eight Sleep, the startup behind the $2,999 mattress cover that puts both Elon Musk and Mark Zuckerberg to…
First-in-Class Therapy Targets “Undruggable” Protein in Hard-to-Treat Blood Cancers
The MYC protein is involved in about 70% of cancers, but scientists have been unable to develop drugs that effectively block it Researchers discovered a dependent relationship in which MYC…
You Want To Join a Clinical Trial. Here’s What To Know About the Hurdles.
Connecting people with clinical trials is complicated — even if people identify a promising match, there’s a slew…
From GLP-1 hormone to weight-loss drug: How semaglutide is made and why quality matters
What does it really take to recreate one of today’s most talked-about medicines? As semaglutide gains traction worldwide,…
Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study
Adult B-ALL exhibits significant heterogeneity and poor prognosis compared with the pediatric population. While the complete remission (CR)…
En Carta Diagnostics Secures €5M to Advance At-Home Molecular Testing
En Carta Diagnostics, a startup developing molecular diagnostics for at-home use, has secured €5 million (approximately $5.8 million)…
Researchers at Wayne State University and Indiana University Working to Develop Next-Generation Cancer Therapies by Switching Off Cancer’s DNA Repair Machinery
Newswise — DETROIT — Cancer treatments like radiation and chemotherapy work by doing one main thing: shredding the…
An Oral Ketamine Drug for Depression — Minus the Trip?
A novel oral ketamine drug was well tolerated and associated with reduced depressive symptoms in treatment-resistant depression (TRD)…
Cutting-Edge Drug Shows Promise for Patients with NRAS-Driven Melanoma
Newswise — A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be…
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
TG Therapeutics, Inc. Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60…
NIH Study: Blood Test Using Circular RNAs Predicts Alzheimer’s Progression
Elevated levels of specific circular RNAs in the blood nearly tripled the risk of developing Alzheimer’s disease symptoms,…
GLP-1s for Addiction: Are We There Yet?
Substance use disorders (SUDs) may become the next therapeutic target for GLP-1 receptor agonists (GLP-1s). Although the evidence…